Compare ADMA Biologics Inc (ADMA) vs Sony Group Corp (SONY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Sony Group Corp — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Sony Group Corp trades at $21.21 (market cap $127.11B). The key difference: Sony Group Corp is far larger — about 59.7× ADMA Biologics Inc's market cap, and Sony Group Corp pays a 0.74% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SONY | |
|---|---|---|
Market Cap | $2.13B | $127.11B |
Sector | Health | Technology |
52-Week High | $20.38 | $30.26 |
52-Week Low | $7.60 | $19.32 |
Enterprise Value | $2.20B | $123.60B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Sony's stock trades at $21.40, up 2.93% today, with a bullish technical signal from moving averages. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company reported strong 2025 revenue of $12.96 trillion and net income of $1.14 trillion, though 2026 projections indicate a net loss. Analyst sentiment is positive, with 68.75% recommending buy. Recent news highlights Sony's shift to digital-only game discs by 2028, sparking consumer backlash.
The outlook is cautiously optimistic due to strong analyst support and solid cash flow, but risks include the negative profit margin forecast for 2026 and market reaction to the digital transition. Investors should weigh the company's innovation efforts against execution risks in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
